Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $217.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target lifted by HC Wainwright from $200.00 to $217.00 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other research reports. Royal Bank of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Robert W. Baird lifted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Barclays reissued an “overweight” rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, Piper Sandler reissued an “overweight” rating and set a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Buy” and a consensus target price of $190.53.

Jazz Pharmaceuticals Stock Down 2.0 %

Shares of NASDAQ:JAZZ opened at $134.16 on Monday. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $148.06. The company has a 50 day moving average of $128.92 and a 200-day moving average of $120.49. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $8.15 billion, a price-to-earnings ratio of 18.90, a P/E/G ratio of 1.04 and a beta of 0.44.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Neena M. Patil sold 3,800 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock worth $4,022,825 over the last ninety days. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of JAZZ. IFP Advisors Inc bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $25,000. Quadrant Capital Group LLC lifted its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP lifted its position in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 183 shares during the period. CoreFirst Bank & Trust bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $28,000. Finally, Allianz SE bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $29,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.